FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:1715 June 10, 1993 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by The Parkinson Study Group

To the Editor: Is it not time to read between the lines? The recent partial retraction of the preliminary, enthusiastic report after additional follow-up by the Parkinson Study Group (Jan. 21 issue)¹ has greatly diminished the previous claims of a protective effect of deprenyl in patients with early untreated Parkinson's disease and has enhanced the known symptomatic effect of this agent^2,3.

Many obvious questions remain. Why have the results of objective biochemical studies related to the predicted attenuation of cerebrospinal fluid homovanillic acid that was an important part of the initial protocol⁴ not been revealed? Have these findings not . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.